<DOC>
	<DOC>NCT02532764</DOC>
	<brief_summary>A randomized, double-blind, placebo-controlled study of single and multiple ascending doses of QR-010 in adults homozygous for ΔF508 Cystic Fibrosis.</brief_summary>
	<brief_title>Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients</brief_title>
	<detailed_description>The purpose of this study is to evaluate the safety, tolerability, and to determine the pharmacokinetics of QR-010 administered via inhalation in adult homozygous for ΔF508 Cystic Fibrosis.</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Confirmed diagnosis of CF as defined by iontophoretic pilocarpine sweat chloride test (sweat chloride) of &gt; 60 mmol/L Confirmation of CFTR gene mutations homozygous for the ΔF508 mutation Body mass index (BMI) ≥ 17 kg/m2 Nonsmoking for a minimum of two years FEV1 ≥70% of predicted normal for age, gender, and height, at Screening Stable lung function Adequate hepatic and renal function Breast‐feeding or pregnant Use of lumacaftor or ivacaftor Use of any investigational drug or device History of lung transplantation Hemoptysis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>ΔF508</keyword>
	<keyword>RNA therapies</keyword>
	<keyword>antisense oligonucleotide</keyword>
	<keyword>CFTR</keyword>
	<keyword>F508del</keyword>
	<keyword>CF</keyword>
	<keyword>RNA therapy</keyword>
</DOC>